Cathie Wood Invests in Moderna After Stock Plunge: Should You Follow?

Cathie Wood, known for investing in undervalued growth stocks, recently bought more Moderna shares after their sharp decline due to the company lowering its revenue forecast. Moderna, famous for its COVID-19 vaccine, faced declining revenue as demand for the vaccine decreased. Despite earlier optimism about new products like its RSV vaccine, Moderna lowered its sales forecast due to lower-than-expected EU sales, slow RSV vaccine adoption, and potential revenue deferrals. This raises the question of whether investors should follow Wood`s lead, considering Moderna`s challenges and future potential.